Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Yet another Cancer...

    Yet another Cancer Causing impurity flagged in blood pressure drug Valsartan

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-19T12:01:18+05:30  |  Updated On 13 Aug 2021 4:28 PM IST

    Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful.


    Connecticut-based Valisure informed the U.S. Food and Drug Administration in a citizen petition last week that it had found through its own testing an impurity called dimethylformamide (DMF) in some batches of the drug. DMF is classified as a probable human carcinogen by the World Health Organization.

    The findings were first reported by Bloomberg earlier on Tuesday.

    Read Also: Valsartan suppliers faulted over data, bugs, dirt: Report

    The FDA said it would review the petition, but "it is important to note that the amounts of DMF being reported are more than 100 times less than those determined by international standards as the level of concern to patients."

    Valisure analyzed valsartan from multiple manufacturers including Novartis AG and several generic manufacturers. Valsartan is the generic name of Novartis' Diovan.

    The amount of DMF found ranged from 8 nanograms per pill to over 100,000 nanograms per pill, the pharmacy said. All were significantly below the current permissible level of 8.8 milligrams per day.

    In its petition, the pharmacy called the FDA standard too high and asked regulators to lower the acceptable intake limit for DMF to match that of other probable carcinogens that have been found in valsartan - N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA).

    DMF is widely used in the production of active ingredients for medicines but is classified by the FDA as a Class 2 solvent, which must be "limited in pharmaceutical products because of its inherent toxicity".

    While the FDA has been investigating the presence of certain impurities in a class of hypertension drugs called angiotensin II receptor blockers (ARBs), including valsartan, this is the first time DMF has been linked to the pills.

    It is also the first time a possible impurity has been flagged in Diovan, the branded version of valsartan.

    Read Also: Lupin, Aurobindo Pharma recalls multiple lots of BP drug including VALSARTAN

    Generic valsartan has been recalled by several companies, including Teva Pharmaceutical Industries Ltd and Mylan NV, after a Chinese bulk manufacturer recalled the product from the U.S. market last July after detecting the presence of NDMA.

    Novartis said DMF is not used in its internal manufacturing processes for Diovan.

    However, the company "cannot currently fully exclude the possibility that traces of DMF (within applicable limits) may have been present in materials of other drug substances suppliers," Novartis spokesman Eric Althoff said in an emailed statement.
    Blood Pressure DrugdimethylformamideDMFdrugsN-nitrosodiethylamineN-nitrosodimethylamineNDEANDMANovartis AGOnline PharmacyOnline pharmacy ValisureUnited StatesUS Food and Drug Administration
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok